Systemic Anti-Cancer Therapy Regimen Library
GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab
Treatment Overview
Cycles 1 to 4 - 21 days
Administer pembrolizumab first followed by ipilimumab; commence ipilimumab no earlier than 30 minutes after completion of the pembrolizumab infusion.
Cycle details
Cycles 1 to 4 - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| pembrolizumab * | 200 mg flat dosing | intravenous | 1 | 30 minutes |
| ipilimumab * | 1 mg/kg | intravenous | 1 | 30 minutes |
Administer pembrolizumab first followed by ipilimumab; commence ipilimumab no earlier than 30 minutes after completion of the pembrolizumab infusion.
Full details
Cycles 1 to 4 - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| pembrolizumab * | 200 mg flat dosing | intravenous | 30 minutes |
Instructions:
Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 5 micron in-line or add-on filter. |
| ipilimumab * | 1 mg/kg | intravenous | 30 minutes |
Instructions:
Commence no earlier than 30 minutes after completion of the pembrolizumab infusion. Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 1.2 micron in-line filter. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Minimal |
| Hypersensitivity / Infusion related reaction risk: | Low - routine premedication not recommended |
References
Merck Sharp & Dohme (New Zealand) Limited. Keytruda New Zealand Data Sheet 21 July 2022. https://www.medsafe.govt.nz/profs/Datasheet/k/Keytruda.pdf (Accessed 29 September 2022).
Bristol-Myers Squibb (NZ) Limited. Yervoy New Zealand Data Sheet 11 March 2021. https://www.medsafe.govt.nz/profs/Datasheet/y/yervoyinj.pdf (Accessed 14 June 2021).
Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.